The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

[1]  C. Rochlitz,et al.  Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Gaze,et al.  177Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma , 2011, The Journal of Nuclear Medicine.

[3]  Matthias Briel,et al.  Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Reubi,et al.  Somatostatin Receptors as Targets for Nuclear Medicine Imaging and Radionuclide Treatment , 2011, The Journal of Nuclear Medicine.

[5]  L. Królicki,et al.  Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  F. Forrer,et al.  Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  S. Walrand,et al.  Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging? , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[9]  J. Hainsworth,et al.  Everolimus plus octreotide LAR (E+O) versus placebo plus octreotide LAR (P+O) in patients with advanced neuroendocrine tumors (NET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-2). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Coppola,et al.  First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas , 2011, Cancer.

[11]  Y. Menda,et al.  Phase I Trial of 90Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors , 2010, The Journal of Nuclear Medicine.

[12]  G. Rindi.  3. The ENETS Guidelines: The New TNM Classification System , 2010, Tumori.

[13]  R. Baum,et al.  Therapeutic nuclear medicine in pediatric malignancy. , 2010, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[14]  W. Oyen,et al.  Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  R. Valkema,et al.  Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  E. Van Cutsem,et al.  90Y-edotreotide for metastatic carcinoid refractory to octreotide. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  E. Baudin,et al.  Daily Oral Everolimus Activity in Patients with Metastatic Pancreatic Neuroendocrine Tumors after Failure of Cytotoxic Chemotherapy: A Phase II Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Marion de Jong,et al.  Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. , 2010, Endocrine-related cancer.

[19]  A Rossi,et al.  Dosimetry for treatment with radiolabelled somatostatin analogues. A review. , 2010, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[20]  Anders Sundin,et al.  Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  J. Bloem,et al.  RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline , 2009, European Radiology.

[22]  Thomas J Vogl,et al.  Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. , 2009, European journal of radiology.

[23]  I. Modlin,et al.  Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours , 2009, Alimentary pharmacology & therapeutics.

[24]  C. Schade-Brittinger,et al.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Pavel,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Chemotherapy in Patients with Neuroendocrine Tumors , 2009, Neuroendocrinology.

[26]  Ashley B. Grossman,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Follow-Up and Documentation , 2009, Neuroendocrinology.

[27]  J. Reubi,et al.  Highly Efficient In Vivo Agonist-Induced Internalization of sst2 Receptors in Somatostatin Target Tissues , 2009, Journal of Nuclear Medicine.

[28]  E. Krenning,et al.  Effects of therapy with [177Lu-DOTA0,Tyr3]octreotate on endocrine function , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  C. Rochlitz,et al.  [90Yttrium‐DOTA]‐TOC response is associated with survival benefit in iodine‐refractory thyroid cancer , 2009, Cancer.

[30]  P Segars,et al.  Evaluation of quantitative planar 90Y bremsstrahlung whole-body imaging , 2009, Physics in medicine and biology.

[31]  R. Dierckx,et al.  Peptide receptor therapies in neuroendocrine tumors , 2009, Journal of endocrinological investigation.

[32]  M. Cremonesi,et al.  Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[33]  Marion de Jong,et al.  Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[34]  G. Kaltsas,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological Examinations , 2008, Neuroendocrinology.

[35]  Giovanni Paganelli,et al.  Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[36]  D. Morris,et al.  Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases , 2008, Cancer.

[37]  C. Nutting,et al.  Radioembolization for Unresectable Neuroendocrine Hepatic Metastases Using Resin 90Y-Microspheres: Early Results in 148 Patients , 2008, American journal of clinical oncology.

[38]  J. Ajani,et al.  A phase II study of irinotecan and cisplatin for metastatic or unresectable high grade neuroendocrine carcinoma , 2008 .

[39]  E. Krenning,et al.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  K. Hess,et al.  Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  K. Ahrar,et al.  Hepatic Arterial Embolization and Chemoembolization in the Management of Patients with Large-Volume Liver Metastases , 2008, CardioVascular and Interventional Radiology.

[42]  M. Vatn,et al.  Treatment with Combined Streptozotocin and Liposomal Doxorubicin in Metastatic Endocrine Pancreatic Tumors , 2008, Neuroendocrinology.

[43]  E. Krenning,et al.  Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[44]  C. Rochlitz,et al.  Response to [90Yttrium-DOTA]-TOC Treatment is Associated with Long-term Survival Benefit in Metastasized Medullary Thyroid Cancer: A Phase II Clinical Trial , 2007, Clinical Cancer Research.

[45]  A. Scarpa,et al.  Consensus Guidelines for the Management of Patients with Liver Metastases from Digestive (Neuro)endocrine Tumors: Foregut, Midgut, Hindgut, and Unknown Primary , 2007, Neuroendocrinology.

[46]  A. Scarpa,et al.  Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumours: Well-Differentiated Colon and Rectum Tumour/Carcinoma , 2007, Neuroendocrinology.

[47]  B. Wiedenmann,et al.  Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors – Well-Differentiated Jejunal-Ileal Tumor/Carcinoma , 2007, Neuroendocrinology.

[48]  M. Falconi,et al.  Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumours: Well-Differentiated Tumour/Carcinoma of the Appendix and Goblet Cell Carcinoma , 2007, Neuroendocrinology.

[49]  Richard P Baum,et al.  Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. , 2007, Cancer biotherapy & radiopharmaceuticals.

[50]  Glenn D. Flux,et al.  Dosimetry for 90Y-DOTATOC therapies in patients with neuroendocrine tumors , 2007 .

[51]  S. Dosso,et al.  Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? , 2007, Cancer Chemotherapy and Pharmacology.

[52]  B. Wiedenmann,et al.  Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: Why Such Guidelines and How We Went about It , 2007, Neuroendocrinology.

[53]  E. Krenning,et al.  Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[54]  B. Diggs,et al.  Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. , 2006, Surgery.

[55]  Giampiero Tosi,et al.  Dosimetry in Peptide radionuclide receptor therapy: a review. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[56]  M. Ferrari,et al.  Radiation protection in radionuclide therapies with 90Y-conjugates: risks and safety , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[57]  G. Paganelli,et al.  Radionuclide peptide cancer therapy , 2006 .

[58]  I. Virgolini,et al.  Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[59]  Jeffrey W. Clark,et al.  Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  P. Hellman,et al.  Midgut carcinoid tumours: surgical treatment and prognosis. , 2005, Best practice & research. Clinical gastroenterology.

[61]  Michael G Stabin,et al.  OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[62]  A. Merlo,et al.  Three‐year recurrence‐free survival in a patient with recurrent medulloblastoma after resection, high‐dose chemotherapy, and intrathecal Yttrium‐90‐labeled DOTA0‐D‐Phe1‐Tyr3‐octreotide radiopeptide brachytherapy , 2005, Cancer.

[63]  Douglas B. Evans,et al.  Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  E. Van Cutsem,et al.  Rapid and Sustained Relief from the Symptoms of Carcinoid Syndrome: Results from an Open 6-Month Study of the 28-Day Prolonged-Release Formulation of Lanreotide , 2004, Neuroendocrinology.

[65]  J. Unützer,et al.  National Institutes of Health State-of-the-Science Conference Statement: Symptom Management in Cancer: Pain, Depression, and Fatigue, July 15-17, 2002. , 2003, Journal of the National Cancer Institute.

[66]  M. Cremonesi,et al.  Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues: ten years experience , 2008 .

[67]  M. Cremonesi,et al.  A comparison of 111In-DOTATOC and 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[68]  P. Bartenstein,et al.  Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[69]  M. Cremonesi,et al.  Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[70]  R. Navickis,et al.  A systematic review of the comparative safety of colloids. , 2004, Archives of surgery.

[71]  W. Oyen,et al.  111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[72]  L. Kvols,et al.  86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[73]  E. Krenning,et al.  New advances in peptide receptor radionuclide therapy. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[74]  R. Valkema,et al.  Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. , 2002, Seminars in nuclear medicine.

[75]  H. Herzog,et al.  Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of 86Y-DOTATOC and 111In-DTPA-octreotide , 2001, European Journal of Nuclear Medicine.

[76]  E. Krenning,et al.  [177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients , 2001, European Journal of Nuclear Medicine.

[77]  P. Ruszniewski,et al.  Hepatic Arterial Chemoembolization in the Management of Advanced Digestive Endocrine Tumors , 2000, Digestion.

[78]  K. Öberg.  Interferon in the Management of Neuroendocrine GEP-Tumors , 2000, Digestion.

[79]  J. Reubi,et al.  Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use , 2000, European Journal of Nuclear Medicine.

[80]  Y. Patel.  Somatostatin and Its Receptor Family , 1999, Frontiers in Neuroendocrinology.

[81]  E. Krenning,et al.  Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[82]  B. Wessels,et al.  MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[83]  T. Visser,et al.  Pre‐clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor‐targeted scintigraphy and radionuclide therapy , 1998, International journal of cancer.

[84]  H. Sitter,et al.  Reactions to gelatin plasma expanders , 1994, The Lancet.

[85]  J. K. Martin,et al.  The Management of Patients with Advanced Carcinoid Tumors and Islet Cell Carcinomas , 1994, Annals of Internal Medicine.

[86]  Stephanie Green,et al.  Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria , 1992, Investigational New Drugs.

[87]  S. Lipsitz,et al.  Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. , 1992, The New England journal of medicine.

[88]  L. Kvols,et al.  Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms , 1991, Cancer.

[89]  J. Stockman,et al.  Everolimus for Advanced Pancreatic Neuroendocrine Tumors , 2012 .

[90]  A. Kjaer,et al.  F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors , 2010 .

[91]  C. Rochlitz,et al.  [(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial. , 2009, Cancer.

[92]  R. Jensen,et al.  Gastroenteropancreatic neuroendocrine tumours. , 2008, The Lancet. Oncology.

[93]  C. Hindorf,et al.  Dosimetry for (90)Y-DOTATOC therapies in patients with neuroendocrine tumors. , 2007, Cancer biotherapy & radiopharmaceuticals.

[94]  Giovanni Paganelli,et al.  Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[95]  E. Krenning,et al.  Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[96]  George Sgouros,et al.  Dosimetry of internal emitters. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[97]  Marion de Jong,et al.  Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[98]  J. Unützer,et al.  National Institutes of Health State-of-the-Science Conference Statement: Symptom management in cancer: pain, depression, and fatigue, July 15-17, 2002. , 2004, Journal of the National Cancer Institute. Monographs.

[99]  R. Valkema,et al.  Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[100]  E P Krenning,et al.  [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. , 2001, European journal of nuclear medicine.

[101]  D M Foster,et al.  Developing and testing integrated multicompartment models to describe a single-input multiple-output study using the SAAM II software system. , 1998, Advances in experimental medicine and biology.

[102]  K. Öberg,et al.  An update of the medical treatment of malignant endocrine pancreatic tumors. , 1993, Acta oncologica.

[103]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .